A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing
- 1 February 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 87 (3) , 435-444
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropismInternational Journal of Oncology, 2012
- Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovirCancer Gene Therapy, 2011
- Stem Cell Based Cancer Gene TherapyMolecular Pharmaceutics, 2011
- HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vectorNanomedicine: Nanotechnology, Biology and Medicine, 2011
- HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cellsCancer Letters, 2010
- Identification of Rare Slipknots in Proteins and Their Implications for Stability and FoldingJournal of Molecular Biology, 2007
- The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinaseGene Therapy, 1999
- The structures of thymidine kinase fromHerpes simplexvirus type 1 in complex with substrates and a substrate analogueProtein Science, 1997
- Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Iowa Methodist Medical Center, Des Moines, IowaHuman Gene Therapy, 1994
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989